Analyst firms · Morgan Stanley · VRTX

Morgan Stanley VRTX price target and rating history

Vertex Pharmaceuticals Incorporated (VRTX) · Health Care

Morgan Stanley rates Vertex Pharmaceuticals Incorporated (VRTX) Overweight with a $665 price target, as of its latest action on Sep 2, 2026. It has published 6 rating actions on VRTX since July 2021, including 2 upgrades and 1 downgrade. Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50. Morgan Stanley's $665 is 15% above that.

Current rating
Overweight
Price target
$665
Median target, all firms
$577.50
Actions on VRTX
6

Morgan Stanley price target on VRTX

$665$434$20220222023202420252026
Morgan Stanley price target on VRTX, each point a stated target, July 2021 to September 2026.

Every Morgan Stanley rating on VRTX

How other firms rate VRTX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Leerink PartnersOutperform$594Sep 21, 2026
Morgan StanleyOverweight$665Sep 2, 2026
Truist SecuritiesBuy$542May 27, 2026
Maxim GroupBuy$575Mar 18, 2026
JefferiesBuy$580Mar 10, 2026
OppenheimerOutperform$600Mar 10, 2026
BarclaysOverweight$606Jan 28, 2026
RBC Capital MarketsOutperform$546Jan 22, 2026
BernsteinOutperformJan 12, 2026
UBSBuy$535Jan 7, 2026
Wolfe ResearchOutperform$548Jan 6, 2026

Questions about Morgan Stanley and VRTX

What is Morgan Stanley's price target for VRTX?
Morgan Stanley's latest stated price target for Vertex Pharmaceuticals Incorporated (VRTX) is $665, from its action on Sep 2, 2026.
What is Morgan Stanley's rating on VRTX?
Morgan Stanley rates VRTX Overweight, a bullish rating, as of Sep 2, 2026.
When did Morgan Stanley last change its view on VRTX?
On Sep 2, 2026, Morgan Stanley resumes coverage at Overweight, price target $665.
How does Morgan Stanley's VRTX target compare with other analysts?
Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50. Morgan Stanley's $665 is 15% above that.

More VRTX rating histories

All Morgan Stanley ratingsVRTX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.